Skip to main content
Midas Edge

BRAINSTORM CELL THERAPEUTICS INC

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

BCLI$1.14-7.3%Stored close · as of Jul 8, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Interim Condensed Statements of Changes in Stockholders’ Deficit

STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT**(UNAUDITED)**

​​​​​​​​​​​​​
​​​​​​Additional​​​​​Total
​ · ​ · Common stock · ​ · paid-in · ​ · Treasury · ​ · Accumulated · ​ · stockholders’
​ · Number(**) · Amount · capital · stocks · deficit · equity
Balance as of January 1, 20232,446,272​12​194,910​(116)​(197,821)​(3,015)
Stock-based compensation related to stock and options granted to directors and employees​(1,255)​*​4​—​—​4
Issuance of shares in at-the-market (ATM) offering (Note 7)​120,000​*​3,230​—​—​3,230
Net loss​—​—​—​—​(5,059)​(5,059)
Balance as of March 31, 2023​2,565,017​12​198,144​(116)​(202,880)​(4,840)
Stock-based compensation related to stock and options granted to directors and employees​21,000​*​988​—​—​988
Issuance of shares in at-the-market (ATM) offering (Note 7)​142,433​*​5,299​—​—​5,299
Net loss​—​—​—​—​(5,329)​(5,329)
Balance as of June 30, 2023​2,728,450​12​204,431​(116)​(208,209)​(3,882)
Stock-based compensation related to stock and options granted to directors and employees​22,277​*​548​—​—​548
Issuance of shares for private placement (Note 7)​270,270​*​1,978​—​—​1,978
Net loss​—​—​—​—​(1,226)​(1,226)
Balance as of September 30, 20233,020,997​12​206,957​(116)​(209,435)​(2,582)
  • Represents an amount less than $1.

STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT (UNAUDITED)

​​​​​​​​​​​​​
​​​​​​Additional​​​​​Total
​ · ​ · Common stock · ​ · paid-in · ​ · Treasury · ​ · Accumulated · ​ · stockholders’
​ · Number · Amount · capital · stocks · deficit · deficit
Balance as of January 1, 20244,032,614(**)13​210,258​(116)​(215,013)​(4,858)
Stock-based compensation related to stock and options granted to directors and employees—​*​170​—​—​170
Issuance of shares in at-the-market (ATM) offering (Note 7)​530,532​*​2,539​—​—​2,539
Net loss​—​—​—​—​(3,401)​(3,401)
Balance as of March 31, 2024​4,563,146(**)13​212,967​(116)​(218,414)​(5,550)
Stock-based compensation related to stock and options granted to directors and employees​111,721(**)*​194​—​—​194
Issuance of shares in at-the-market (ATM) offering (Note 7)​107,011(**)*​725​—​—​725
Issuance of shares for private placement (Note 7)​527,918(**)1​3,644​—​—​3,645
Net loss​—​—​—​—​(2,541)​(2,541)
Balance as of June 30, 2024​5,309,796(**)14​217,530​(116)​(220,955)​(3,527)
Stock-based compensation related to stock and options granted to directors and employees​—​*​178​—​—​178
Net loss​—​—​—​—​(2,708)​(2,708)
Balance as of September 30, 20245,309,796​14​217,708​(116)​(223,663)​(6,057)
  • Represents an amount less than $1.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.